GH Research PLC (GHRS) stock
Close on Nov 12, 2026Market cap $1.15BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.15B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -4.52%
Fundamentals
- Net income
- -$62.27M
- EPS, diluted
- -$1.00
- Free cash flow
- -$51.84M
- Diluted shares
- 67M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $19.25
- Open
- $19.01
- Day's range
- $17.96 – $19.09
- Volume
- 191,866
- Average volume (20 days)
- 322,223
- Beta (5 years)
- 1.05
- 52-week range
- $12.04 – $31.44
- RSI (14 days)
- 38.3
- Volatility (1 year)
- 69.8%
- Relative volume
- 0.64×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GHRS | S&P 500 | Difference | GHRS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.6% | -2.7% | −4.9 pts | ||
| 3 months | -38.9% | -1.7% | −37.1 pts | ||
| Year to date | +45.6% | +11.9% | +33.7 pts | ||
| 1 year | +23.3% | +12.0% | +11.3 pts | ||
| 3 years | +125.2% | +78.2% | +47.0 pts | +31.1% | +21.2% |
| 5 years | -16.4% | +73.2% | −89.6 pts | -3.5% | +11.6% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases GH Research filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About GH Research
Pharmaceutical Preparations
GH Research PLC is a clinical-stage biopharmaceutical company that develops novel investigational therapies based on mebufotenin. Its primary product candidates include GH001 and GH002, which are designed to treat medical indications alongside proprietary administration equipment, such as an aerosol delivery device developed for GH001. The company operates without commercial business segments and currently has no approved commercial products. Consequently, it has not yet established a commercial customer base, though its prospective users and end recipients include patients, prescribing medical professionals, and specialized third-party clinics or treatment centers.
Company profile, executives and historyGH Research stock: common questions
What is GH Research's stock price?
GHRS closed at $18.49 on Nov 12, 2026, down 3.95% on the day. Over the past 52 weeks it traded between $12.04 and $31.44.
What is GH Research's market cap?
GH Research was worth $1.15B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is GHRS's P/E ratio?
GH Research lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.00), so it has no meaningful P/E ratio.
Does GH Research pay a dividend?
No. GH Research has not paid a cash dividend over the last twelve months.
When does GH Research report earnings next?
GH Research's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has GHRS stock performed over the past year?
Including dividends, GHRS returned +23.3% over the past year, against +12.0% for the S&P 500.
How many GHRS shares are sold short?
2M shares were sold short at the latest FINRA report, 6.16% of the float, or 6.5 days of average trading volume.
Who are GH Research's competitors?
Companies most similar to GH Research by business, industry and size include GRI, RNTX, YARW, NAMS, CAMP.
See a number that looks wrong?